Seres Therapeutics, Inc. (MCRB) NASDAQ
8.64
+0.315(+3.79%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.64
+0.315(+3.79%)
Currency In USD
| Previous Close | 8.32 |
| Open | 8.75 |
| Day High | 8.75 |
| Day Low | 8.3 |
| 52-Week High | 29.98 |
| 52-Week Low | 6.53 |
| Volume | 19,508.92 |
| Average Volume | 66,298 |
| Market Cap | 82.78M |
| PE | 13.49 |
| EPS | 0.64 |
| Moving Average 50 Days | 9.95 |
| Moving Average 200 Days | 14.76 |
| Change | 0.32 |
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
GlobeNewswire Inc.
Mar 02, 2026 9:05 PM GMT
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support t
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
GlobeNewswire Inc.
Feb 12, 2026 12:00 PM GMT
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while eff
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advanceme